📄 6 mins.

Why Fenbendazole Is Not FDA Approved For Cancer

Fenbendazole is old. It is inexpensive. Laboratory and animal studies have shown it can disrupt cancer cell growth. So why is it not FDA approved for human cancer?

Short answer: no patent, no sponsor, no big trials.
The U.S. drug approval system rewards high-priced, patent-protected drugs. It does not reward cheap generics that anyone can make.

What FDA Approval Really Takes

For a drug to have “for cancer” on its label in the United States, a company must run large, multi-phase clinical trials in people:

• Phase 1 – Safety in a small group of healthy volunteers or patients.
• Phase 2 – Effectiveness and dose in a few hundred patients.
• Phase 3 – Large, controlled trials in hundreds to thousands of patients.

On top of that, there are years of toxicology studies, manufacturing inspections, and endless documentation.

The cost:
A 2020 JAMA study estimated the median total investment to bring a new drug to market is $985 million. For cancer drugs, costs are often higher because trials are longer and more complex. Other industry analyses put the range at $1 to 2 billion when failures are included. If a company cannot protect a drug with a strong patent and high price, they cannot recoup those costs. No profit means no investor interest, which means no trials.

Why There is No Patent

Fenbendazole was developed in the 1970s by Hoechst AG. The core patents expired decades ago. Once patents expire:

• Any manufacturer can produce the drug.
• There is no monopoly to control price.
• There is no way to charge $10,000 or $20,000 a month like with newer cancer drugs.

Could a company file a new patent on a special formulation or a niche cancer use? Yes. But those patents are often narrow, easy to work around, and don’t support sky-high prices. So big companies do not invest.

The Money behind Modern Cancer Treatment

Here is the uncomfortable truth:
Cancer drugs are one of the most profitable sectors in medicine.

• In 2023, new injectable cancer drugs in the U.S. averaged $27,688 per month.
• Many launch at $10,000–$30,000 per month and increase in price over time.
• Between 2011 and 2022, the median U.S. launch price for a cancer drug rose from $32,000 to over $220,000 for a typical treatment course.

And for the companies?

• In 2024, Merck’s cancer drug Keytruda made $29.5 billion in global sales – from just one product, in one year.
• The top 10 cancer drugs together brought in well over $100 billion last year.

Now compare that to fenbendazole:
Even if proven effective for some cancers, it would likely cost under $100 per month.
That is not a product Wall Street gets excited about but it is exactly what struggling families need.

What this Means for an Ordinary Family

Picture a truck driver in Texas whose wife needs a $20,000-per-month targeted cancer drug.
Insurance pays most, but the co-pays, travel costs, unpaid time off, and hotel stays near the cancer center still crush the budget.
They sell their second car.
They max out credit cards.
They skip home repairs and grocery shop with coupons.
The stress is constant.
This is financial toxicity when the cost of care becomes part of the disease.

The National Cancer Institute reports that 42% of cancer patients exhaust their life savings within two years of diagnosis.
Patients skip doses, delay scans, or stop treatment because they cannot pay.
A safe, low-cost drug could change this.
But in today’s system, profit, not potential, decides what gets tested.

Medicaid, Medicare, and the Squeeze

Medicaid serves low-income patients, but states use prior authorizations and drug restrictions to control costs. This can mean delays or outright denials.
For people on Medicare, out-of-pocket caps are improving, but even the $2,000 annual cap (coming in 2025 for covered drugs) is a heavy lift for someone living on Social Security.

A drug like fenbendazole (if ever approved) would be inexpensive enough to dramatically reduce these burdens.
But the system does not reward companies for proving it works.

Why Big Pharma Will NOT Touch It

1. No core patent – no monopoly pricing.
2. Too cheap – not enough revenue to justify billion-dollar trials.
3. Better ROI elsewhere – companies put their trial budgets into drugs that can earn billions per year.

Who Loses When Repurposed Drugs are Ignored

Patients lose options. Doctors cannot prescribe a drug for cancer without evidence from large trials, and insurance will not cover it.
Families lose savings. The high cost of brand-name cancer drugs is a major driver of medical bankruptcy in the U.S.
Science loses opportunities. Every time an old, promising molecule is ignored, we might be leaving a useful treatment undiscovered.

Bottom Line

Fenbendazole is not FDA approved for cancer because there is no financial incentive to fund the huge human trials needed for approval.
The drug is off-patent, inexpensive, and cannot be sold at monopoly prices.
Meanwhile, the cancer drug market is built on treatments that cost tens of thousands of dollars a month and bring in tens of billions of dollars a year.

The science behind fenbendazole deserves a fair test.
The families facing bankruptcy for life-saving treatment deserve it even more.
Until we put patient health above corporate profit, old and affordable options will continue to be ignored, not because they do not work, but because they do not make enough money.

Many people who turn to alternative treatments like fenbendazole feel a deep sense of hesitation – not because they don’t believe in their potential, but because these options aren’t backed by large clinical trials and often come with heavy social pressure to avoid them. Friends, doctors, and even family may dismiss their choices, leaving them anxious or isolated in a moment when they most need support. Yet choosing alternatives can also be an act of courage and self-determination, rooted in the belief that healing isn’t one-size-fits-all. We’ve written an article about the psychology of choosing alternative paths and how to cope with the doubts and pressures that come with it, you can read it here: https://www.fenbendazole.org/the-psychology-of-choosing-fenbendazole/

References

• Google Patents. US3954791A. Hoechst patent family describing benzimidazole anthelmintics. Confirms 1970s origin and expired status. Google Patents
• Wouters OJ, et al. Estimated research and development investment needed to bring a new medicine to market. JAMA. 2020. Median capitalized cost near one billion dollars. PubMed
• Michaeli DT, et al. Launch and post-launch prices of injectable cancer drugs. 2005 to 2023 price trends. Mean monthly price about 27,688 dollars in 2023. PubMed
• Laube Y, et al. Launch price trends for new drugs in the U.S. JAMA Health Forum. 2024. Launch prices rose sharply between 2011 and 2022. JAMA Network
• Merck. Full-year 2024 results. Keytruda sales about 29.5 billion dollars. Press release and earnings deck. Merck.coms21.q4cdn.com
• NCI. Financial Toxicity and Cancer Treatment. PDQ pages updated 2024. Summarizes the burden of costs on patients and families. Cancer.gov+1
• MACPAC. Prior Authorization in Medicaid. 2024. Explains how states rely on prior authorization to manage drug spending, which can delay access. MACPAC
• CMS and HHS ASPE. Medicare Part D changes. Out-of-pocket cap of 2,000 dollars in 2025 for covered drugs. Centers for Medicare & Medicaid ServicesASPE